+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neulasta"

Neutropenia Biologic Drug Treatment Global Market Report 2024 - Product Thumbnail Image

Neutropenia Biologic Drug Treatment Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Neutropenia - Pipeline Insight, 2024 - Product Thumbnail Image

Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Neulasta is a drug used to treat immune disorders, such as neutropenia, a condition in which the body does not produce enough white blood cells. Neulasta is a type of biologic therapy, which is a type of drug that is made from living cells. It works by stimulating the production of white blood cells, which helps the body fight infection. Neulasta is typically used in combination with chemotherapy to reduce the risk of infection in cancer patients. It is also used to treat other immune disorders, such as rheumatoid arthritis and Crohn's disease. Neulasta is a widely used drug in the immune disorders market, and is available in both injectable and subcutaneous forms. It is typically administered in a hospital or clinic setting, and is usually given once a month. The drug is typically well-tolerated, with few side effects. Companies in the Neulasta market include Amgen, Pfizer, and Johnson & Johnson. Show Less Read more